ANAPTYSBIO, INC. Debt Securities, Available-for-sale, Unrealized Loss
ANAPTYSBIO, INC. (ANAB) reported Debt Securities, Available-for-sale, Unrealized Loss of $3.70 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-08-08
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $1.50M.
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $2.20M.
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2021-06-30 was $0.00.
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2021-03-31 was $0.00.
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for fiscal 2020 was $0.00.
- ANAPTYSBIO, INC. debt securities, available-for-sale, unrealized loss for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month as first filed |
|---|---|---|---|---|
| 2022-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.70M 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $2.20M 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $200.00K 10-Q · filed 2022-08-08 | $0.00 10-K · filed 2022-03-07 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-07 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |